Pharmacological Study of Modified Intermediate-dose Cytarabine Therapy in Patients with Acute Myeloid Leukemia

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5037-5042

  Sutoh, Hidemasa ^a   Yamauchi, Takahiro ^a   Gotoh, Nobuyuki ^a   Sugiyama, Masatoshi ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

1 D arabinofuranosylcytosine; Modified intermediate dose; Pharmacokinetics

Indexed keywords

ACLARUBICIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ENOCITABINE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PIRARUBICIN; URACIL ARABINOSIDE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; STEADY STATE; URINARY EXCRETION;

ACUTE DISEASE; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED;

EID: 0842343490     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rowe JM: What is the best induction regimen for acute myelogenous leukemia? Leukemia 12 Suppl 1: S16-19, 1998.
2. Estey EH: Therapeutic options for acute myelogenous leukemia. Cancer 92: 1059-1073, 2001.
3. Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA and Estey EH: Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21: 1722-1727, 2003.
4. 4-behenoyl-1-β -D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 43: 3412-3416, 1983.
5. 4-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res 92: 975-982, 2001.
6. Early AP, Preisler HD, Slocum H and Rusrum YM: A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology. Cancer Res 42: 1587-1594, 1982.
7. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D'Arrigo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A and Bennett J: High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a leukemia intergroup study. J Clin Oncol 5: 75-82, 1987.
8. Miyawaki S, Mizoguchi H, Tomonaga M, Kanamaru A, Tsukagoshi S, Nakamura T, Ohashi Y, Yoshida S and Ohno R: A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia. Jpn J Cancer Chemother 25: 2229-2242, 1998.
9. Harris AL and Grahame-Smith DG: Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukemia. Br J Haematol 45: 371-379, 1980.
10. van Prooijen HC, Dekker AW and Punt K: The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukemia in relapse. Br J Haematol 57: 291-299, 1984.
11. Tattersall MNH, Ganeshaguru K and Hoffbrand AV: Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br J Haematol 27: 39-46, 1974.
12. Steuart CD and Burke PJ: Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 233: 109-110, 1971.
13. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH and Finch LR: Cytosine aravinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75: 632-642, 1985.
14. Ho DHW and Frei E III: Clinical pharmacology of 1-β -D-arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944-954, 1971.
15. Ueda T, Kamiya K, Fukushima T, Tsutani H, Kagawa D, Sugiyama M, Domae N and Nakamura T: Clinical pharmacology of intermediate dose ara-C therapy in patients with acute leukemia. Jpn J Clin Pharmacol Ther 20: 119-120, 1989.
16. Linssen P, Drenthe-Schonk A, Wessels H and Haanen C: Determination of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil in human plasma by high-performance liquid chromatography. J Chromatogr 223: 371-378, 1981.
17. Yamaoka K and Tanigawara Y: A primer on pharmacokinetics using a microcomputer. In: Automated Pharmacokinetic Analysis System. Nankoudo, Tokyo. 1983, pp.159
18. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T: A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4: 879-885, 1981.
19. Yamaoka K, Nakagawa T and Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165-175, 1978.
20. Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M and Ueda T: Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses. Jpn J Cancer Res 92: 546-553, 2001.
21. Garcia-Carbonero R, Ryan DP and Chabner BA: Cytidine analogues. In: Cancer Chemotherapy and Biotherapy. 3rd ed. (Chabner BA and Longo DL, eds.) Lippincott-Raven Publishers, Philadelphia; 2001. pp265-294.
22. Matsuyama S, Ueda T, Yamauchi T, Kawai Y, Kamiya K Nakamura T, Gotoh N and Masada M: Plasma pharmacokinetics of low-dose cytarabine in patients with leukemia and myelodysplastic syndrome. Jpn J Clin Pharmacol Ther 26: 439-440, 1995.
23. Yang JL, Cheng EH, Capizzi RL, Cheng YC and Kute T: Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. J Clin Invest 75: 141-146, 1985.
24. Slevin ML, Piall EM, Aherne GW, Johnston A and Lister TA: The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol Suppl 1: 157-168, 1982.
25. Bleyer WA and Byrne TN: Leptomeningeal cancer in leukemia and solid tumors. Curr Probl Cancer 12: 181-238, 1988.